Mechanisms of enhanced vasoconstriction in the mouse model of atherosclerosis: The beneficial effects of sildenafil

Current Pharmaceutical Biotechnology

Volumn 16, Issue 6, 2015, Pages 517-530

  Leal, Marcos A ^a   Balarini, Camille M ^b   Dias, Ananda T ^a   Porto, Marcella L ^a   Gava, Agata L ^a   Pereira, Thiago M C ^c,d   Meyrelles, Silvana S ^a   Vasquez, Elisardo C ^a,c,e  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^c UNIVERSIDADE VILA VELHA   (Brazil)

^d Federal Institute of Education   (Brazil)

^e Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

Author keywords

ApoE knockout mice; Atherosclerosis; Endothelial dysfunction; Nitric oxide; Oxidative stress; Sildenafil

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SILDENAFIL; APOLIPOPROTEIN E; PHOSPHODIESTERASE V INHIBITOR; REACTIVE OXYGEN METABOLITE; VASODILATOR AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOSE RESPONSE; DRUG BIOAVAILABILITY; ENDOTHELIAL DYSFUNCTION; LINEAR REGRESSION ANALYSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; VASOCONSTRICTION; ANIMAL; ARTERIAL STIFFNESS; C57BL MOUSE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; YOUNG MODULUS;

MUS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIC MODULUS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OXIDATIVE STRESS; PHOSPHODIESTERASE 5 INHIBITORS; REACTIVE OXYGEN SPECIES; SILDENAFIL CITRATE; TREATMENT OUTCOME; VASCULAR STIFFNESS; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 84928943415     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920101606150407113458     Document Type: Article

References (66)

1. [I] Vane, J.R. The Croonian Lecture, 1993. The endothelium: maestro of the blood circulation. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1994, 343(1304), 225-246
2. Versari, D.; Daghini, E.; Virdis, A.; Ghiadoni, L.; Taddei, S. Endo- thelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care, 2009, 32(Suppl 2), S314-321
3. Meyrelles, S.S.; Peotta, V.A.; Pereira, T.M.C.; Vasquez, E.C. En- dothelial dysfunction in the apolipoprotein E-deficient mouse: Insights into the influence of diet, gender and aging. Lipids Health Dis., 2011, 14, 10, 211
4. Libby, P.; Ridker, P.M.; Hansson, G.K. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347), 317-325
5. 5] Arruda, R.M.; Peotta, V.A.; Meyrelles, S.S.; Vasquez, E.C. Evalua- tion of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension, 2005, 46(4), 932-936
6. Kraus, S.; Naumov, I.; Shapira, S.; Kazanov, D.; Aroch, I.; Afek, A.; Eisenberg, O.; George, J.; Arber, N.; Finkelstein, A. Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. Isr. Med. Assoc. J., 2014, 16(4), 233-238
7. Vasquez, E.C.; Peotta, V.A.; Gava, A.L.; Pereira, T.M.; Meyrelles, S.S. Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J. Biomed. Sci., 2012, 19, 22
8. Taichman, D.B.; Ornelas, J.; Chung, L.; Klinger, J.R.; Lewis, S.; Mandel, J.; Palevsky, H.I.; Rich, S.; Sood, N.; Rosenzweig, E.B.; Trow, T.K.; Yung, R.; Elliott, C.G.; Badesch, D.B. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest, 2014, 146(2), 449-475
9. Dias, A.T.; Rodrigues, B.P.; Porto, M.L.; Gava, A.L.; Balarini, C.M.; Freitas, F.P.; Palomino, Z.; Casarini, D.E.; Campagnaro, B.P.; Pereira, T.C.M.; Meyrelles, S.S.; Vasquez, E.C. Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension. J. Transl. Med., 2014, 12, 35
10. Rodrigues, B.P.; Campagnaro, B.P.; Balarini, C.M.; Pereira, T.M.C.; Meyrelles, S.S.; Vasquez, E.C. Sildenafil ameliorates bio-markers of genotoxicity in an experimental model of spontaneous atherosclerosis. Lipids Health Dis., 2013, 12, 128
11. Balarini, C.M.; Leal, M.A.; Gomes, I.B.; Pereira, T.M.C.; Gava, A.L.; Meyrelles, S.S.; Vasquez, E.C. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse J. Transl. Med., 2013, 11, 3
12. Dias, A.T.; Cintra, A.S.; Frossard, J.C.; Palomino, Z.; Casarini, D.E.; Gomes, I.; Balarini, C.M.; Gava, A.L.; Campagnaro, B.P.; Pereira, T.M.C.; Meyrelles, S.S.; Vasquez, E.C. Inhibition of phos-phodiesterase 5 restores endothelial function in renovascular hypertension. J. Transl. Med., 2014, 12(1), 250
13. Tonini, C.L.; Campagnaro, B.P.; Louro, L.P.; Pereira, T.M.; Vasquez, E.C.; Meyrelles, S.S. Effects of aging and hypercholes-terolemia on oxidative stress and DNA damage in bone marrow mononuclear cells in apolipoprotein E-deficient mice. Int. J. Mol. Sci., 2013, 14(2), 3325-3342
14. Das, A.; Durrant, D.; Mitchell, C.; Mayton, E.; Hoke, N.N.; Sal-loum, F.N.; Park, M.A.; Qureshi, I.; Lee, R.; Dent, P.; Kukreja, R.C. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc. Natl. Acad. Sci. USA, 2010, 107(42), 18202-18207
15. Nguyen, H.; Amanullah, A.M. Therapeutic potentials of phos-phodiesterase-5 inhibitors in cardiovascular disease. Rev. Cardio-vasc. Med., 2014, 15(2), 158-167
16. Koka, S.; Das, A.; Salloum, F.N.; Kukreja, R.C. Phosphodi-esterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. Free Radic. Biol. Med., 2013, 60, 80-88
17. Guazzi, M.; Vicenzi, M.; Arena, R.; Guazzi, M.D. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation, 2011, 124(2), 164-174
18. Santos, R.C.; de Faria, A.P.; Barbaro, N.R.; Modolo, R.; Ferreira-Melo, S.E.; Matos-Souza, J.R.; Coelho, O.R.; Yugar-Toledo, J.C.; Fontana, V.; Calhoun, D.; Moreno, H. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur. J. Clin. Pharmacol., 2014, 70(2), 147-154
19. Urbanowicz, T.; Straburzyńska-Migaj, E.; Katyńska, I.; Arasz-kiewicz, A.; Oko-Sarnowska, Z.; Grajek, S.; Jemielity, M. Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil. Ann. Transplant., 2014, 19, 325-330
20. Gatzoulis, M.A.; Alonso-Gonzalez, R.; Beghetti, M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur. Respir. Rev., 2009, 18(113), 154-161
21. Hansdottir, S.; Groskreutz, D.J.; Gehlbach, B.K. WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension. Chest, 2013, 144(2), 638-650
22. Zamanian, R.T.; Kudelko, K.T.; Sung, Y.K.; de Jesus Perez, V.; Liu, J.; Spiekerkoetter, E. Current clinical management of pulmonary arterial hypertension. Circ. Res., 2014, 115(1), 131-147
23. Giannetta, E.; Feola, T.; Gianfrilli, D.; Pofi, R.; Dall'Armi, V.; Badagliacca, R.; Barbagallo, F.; Lenzi, A.; Isidori, A.M. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med., 2014, 12(1), 185
24. Vlachopoulos, C.; Terentes-Printzios, D.; Ioakeimidis, N.; Rokkas, K.; Stefanadis, C. PDE5 inhibitors in non-urological conditions. Curr. Pharm. Des., 2009, 15(30), 3521-3539
25. Yaguas, K.; Bautista, R.; Quiroz, Y.; Ferrebuz, A.; Pons, H.; Franco, M.; Vaziri, N.D.; Rodriguez-Iturbe, B. Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension. Am. J. Nephrol., 2010, 31(4), 283-291
26. Potthoff, S.A.; Fähling, M.; Clasen, T.; Mende, S.; Ishak, B.; Su-vorava, T.; Stamer, S.; Thieme, M.; Sivritas, S.H.; Kojda, G.; Pat-zak, A.; Rump, L.C.; Stegbauer, J. Angiotensin-(1-7) modulates renal vascular resistance through inhibition of p38 mitogen-activated protein kinase in apolipoprotein E-deficient mice. Hypertension, 2014, 63(2), 265-272
27. Cola, M.S.; Gava A.; Meyrelles, S.S.; Vasquez, E.C. Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice. Lipids Health Dis., 2010, 9, 51
28. d'Uscio, L.V.; Baker, T.; Mantilla, C.B.; Smith, L.; Weiler, D.; Sieck, G.C.; Katusic, Z.S. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol., 2001, 21(6), 1017-1022
29. Fransen, P; Van Assche, T.; Guns, P.J.; Van Hove, C.E.; De Keulenaer, G.W.; Herman, A.G.; Bult, H. Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Pflugers Arch., 2008, 455(5), 811-818
30. Capettini, L.S.; Cortes, S.F.; Silva, J.F.; Alvarez-Leite, J.I.; Lemos, V.S. Decreased production of neuronal NOS-derived hydrogen peroxide contributes to endothelial dysfunction in atherosclerosis. Br. J. Pharmacol., 2011, 164(6), 1738-1748
31. Buus, N.H.; Hansson, N.C.; Rodriguez-Rodriguez, R.; Stankevicius, E.; Andersen, M.R.; Simonsen, U. Antiatherogenic effects of oleanolic acid in apolipoprotein E knockout mice. Eur. J. Pharmacol., 2011, 670(2-3), 519-526
32. Csányi, G.; Gajda, M.; Franczyk-Zarow, M.; Kostogrys, R.; Gwoźdź, P.; Mateuszuk, L.; Sternak, M.; Wojcik, L.; Zalewska, T.; Walski, M.; Chlopicki, S. Functional alterations in endothelial NO, PGI2 and EDHF pathways in aorta in ApoE/LDLR-/- mice. Prostaglandins Other Lipid Mediat., 2012, 98(3-4), 107-115
33. Bonthu, S.; Heistad, D.D.; Chappell, D.A.; Lamping, K.G.; Faraci, F.M. Atherosclerosis, vascular remodeling, and impairment of en-dothelium-dependent relaxation in genetically altered hyperlipi-demic mice. Arterioscler. Thromb. Vasc. Biol., 1997, 17(11), 2333-2340
34. Maguire, J.J.; Wiley, K.E.; Kuc, R.E.; Stoneman, V.E.; Bennett, M. R.; Davenport, A.P. Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin. Exp. Biol. Med. (Maywood), 2006, 231(6), 806-812
35. Prendergast, C; Quayle, J.; Burdyga, T.; Wray, S. Atherosclerosis differentially affects calcium signalling in endothelial cells from aortic arch and thoracic aorta in Apolipoprotein E knockout mice. Physiol. Rep., 2014, 2(10)
36. Weisbrod, R.M.; Griswold, M.C.; Du, Y.; Bolotina, V.M.; Cohen, R.A. Reduced responsiveness of hypercholesterolemic rabbit aortic smooth muscle cells to nitric oxide. Arterioscler. Thromb. Vasc. Biol, 1997, 17(2), 394-402
37. Mori-Kawabe, M.; Tsushima, H.; Fujimoto, S.; Tada, T.; Ito, J. Role of Rho/Rho-kinase and NO/cGMP signaling pathways in vascular function prior to atherosclerosis. J. Atheroscler. Thromb. 2009, 16(6), 722-732
38. Ebrahimi, F.; Shafaroodi, H.; Asadi, S.; Nezami, B.G.; Ghasemi, M.; Rahimpour, S.; Hashemi, M.; Doostar, Y.; Dehpour, A.R. Sildenafil decreased cardiac cell apoptosis in diabetic mice: reduction of oxidative stress as a possible mechanism. Can. J. Physiol. Pharmacol. 2009, 87(7), 556-564
39. Koupparis, A.J.; Jeremy, J.Y.; Muzaffar, S.; Persad, R.; Shukla, N. Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int., 2005, 96(3), 423-427
40. Lee, K.C.; Yang, Y.Y.; Huang, Y.T.; Lee, F.Y.; Hou, M.C.; Lin, H.C.; Lee, S.D. Administration of a low dose of sildenafil for 1 week decreases intrahepatic resistance in rats with biliary cirrhosis: the role of NO bioavailability. Clin. Sci. (Lond), 2010, 119(1), 45-55
41. Inan, M.; Uz, Y.H.; Kizilay, G.; Topcu-Tarladacalisir, Y.; Sapmaz-Metin, M.; Akpolat, M.; Aydogdu, N. Protective effect of sildenafil on liver injury induced by intestinal ischemia/ reperfusion. J. Pedi-atr. Surg., 2013, 48(8), 1707-1715
42. McClelland, S.; Gawaz, M.; Kennerknecht, E.; Konrad, C.S.; Sauer, S.; Schuerzinger, K.; Massberg, S.; Fitzgerald, D.J.; Belton, O. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. Atherosclerosis, 2009, 202(1), 84-91
43. Kobayashi, T.; Tahara, Y.; Matsumoto, M.; Iguchi, M.; Sano, H.; Murayama, T.; Arai, H.; Oida, H.; Yurugi-Kobayashi, T.; Yama-shita, J.K.; Katagiri, H.; Majima, M.; Yokode, M.; Kita, T.; Naru-miya, S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest., 2004, 114(6), 784-794.
44. Félétou, M.; Verbeuren, T.J.; Vanhoutte, P.M. Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. Br. J. Pharmacol., 2009, 156(4), 563-574
45. Belton, O.; Byrne, D.; Kearney, D.; Leahy, A.; Fitzgerald, D.J. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation, 2000, 102(8), 840-845.
46. 46] Upmacis, R.K.; Deeb, R.S.; Hajjar, D.P. Oxidative alterations of cyclooxygenase during atherogenesis. Prostaglandins Other Lipid Mediat., 2006, 80(1-2), 1-14
47. Ricciotti, E.; FitzGerald, G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol., 2011, 31(5), 986-1000
48. Paul, B.Z.; Jin, J.; Kunapuli, S.P. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J. Biol. Chem., 1999, 274(41), 29108-29114
49. Santhosh, K.T.; Elkhateeb, O.; Nolette, N.; Outbih, O.; Halayko, A.J.; Dakshinamurti, S. Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes. Br. J. Pharmacol., 2011, 163(6), 1223-1236
50. Shi, Y.; Vanhoutte, P.M. Oxidative stress and COX cause hyper-responsiveness in vascular smooth muscle of the femoral artery from diabetic rats. Br. J. Pharmacol., 2008, 154(3), 639-651
51. Dussault, S.; Maingrette, F.; Ménard, C.; Michaud, S.E.; Haddad, P.; Groleau, J.; Turgeon, J.; Perez, G.; Rivard, A. Sildenafil increases endothelial progenitor cell function and improves ischemia-induced neovascularization in hypercholesterolemic apolipoprotein E-deficient mice. Hypertension, 2009, 54(5), 1043-1049
52. Korom, S.; Hillinger, S.; Cardell, M.; Zhai, W.; Tan, Q.; Dutly, A.; Leskosek, B.; Weder, W. Sildenafil extends survival and graft function in a large animal lung transplantation model. Eur. J. Car-diothorac. Surg., 2006, 29(3), 288-293
53. Pereira, T.M.; Nogueira, B.V.; Lima, L.C.; Porto, M.L.; Arruda, J.A.; Vasquez, E.C.; Meyrelles, S.S. Cardiac and vascular changes in elderly atherosclerotic mice: the influence of gender. Lipids Health Dis., 2010, 9, 87
54. El-Mahmoudy, A.M.; Shousha, S.M.; Abdel-Maksoud, H.; Abouzaid, O. Effect of long-term administration of sildenafil on lipid profile and organ functions in hyperlipidemic rats. Acta Bio-med., 2013, 84(1), 12-22
55. Dai, G.; Kaazempur-Mofrad, M.R.; Natarajan, S.; Zhang, Y.; Vaughn, S.; Blackman, B.R.; Kamm, R.D.; García-Cardeña, G.; Gimbrone, M.A Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc. Natl. Acad. Sci USA, 2004, 101(41), 14871-14876
56. Wasserman, S.M.; Topper, J.N. Adaptation of the endothelium to fluid flow: in vitro analyses of gene expression and in vivo implications. Vasc. Med., 2004, 9(1), 35-45
57. Fleissner, F.; Thum, T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Anti-oxid. Redox Signal., 2011, 15(4), 933-948
58. Foresta, C.; De Toni, L.; Di Mambro, A.; Garolla, A.; Ferlin, A.; Zuccarello, D. The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells and CXCR4 expression. J. Sex Med., 2009, 6(2), 369-372
59. Lima, L.; Porto, M.L.; Campagnaro, B.P.; Tonini, C.L.; Nogueira, B.V.; Pereira, T.M.; Vasquez, E.C.; Meyrelles, S.S. Mononuclear cell therapy reverts cuff-induced thrombosis in apolipoprotein E-deficient mice. Lipids Health Dis., 2012, 11, 96
60. Porto, M.L.; Lima, L.C.; Pereira, T.M.; Nogueira, B.V.; Tonini, C.; Campagnaro, B.P.; Meyrelles, S.S.; Vasquez, E.C. Mononuclear cell therapy attenuates atherosclerosis in apoE KO mice. Lipids Health Dis., 2011, 10, 155
61. Shen, W.C.; Liang, C.J.; Wu, V.C.; Wang, S.H.; Young, G.H.; Lai, I.R.; Chien, C.L.; Wang, S.M.; Wu, K.D.; Chen, Y.L. Endothelial progenitor cells derived from Wharton's jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1α/IL-8 expression. Stem Cells Dev., 2013, 22(9), 1408-1418
62. Foresta, C.; Lana, A.; Cabrelle, A.; Ferigo, M.; Caretta, N.; Garolla, A.; Palù, G., Ferlin, A. PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int. J. Impot. Res., 2005, 17(4), 377-380
63. Foresta, C.; Caretta, N.; Lana, A.; De Toni, L.; Biagioli, A.; Vi-nanzi, C.; Ferlin, A. Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. Eur. Urol., 2007, 51(5), 1411-1417
64. Schwartz, B.G.; Jackson, G.; Stecher, V.J.; Campoli-Richards, D.M.; Kloner, R.A. Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions. Am. J. Med., 2013, 126(3), 192-199
65. Hoke, N.N.; Salloum, F.N.; Kass, D.A.; Das, A.; Kukreja, R.C. Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. Stem Cells, 2012, 30(2), 326-335
66. Kovanecz, I.; Rivera, S.; Nolazco, G.; Vernet, D.; Segura, D.; Gharib, S.; Rajfer, J.; Gonzalez-Cadavid, N.F. Separate or combined treatments with daily sildenafil, molsidomine, or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage. J. Sex Med., 2012, 9(11), 2814-2826.